Concepedia

Rajasekhar N.V.S. Suragani

RN

Statistics

Publications

13

Citations

1.1K

H-Index

10

Active since

2005

Affiliations

Acceleron Pharma (United States)(Current)

Massachusetts Institute of Technology

Harvard–MIT Division of Health Sciences and Technology

Harvard University

TScan Therapeutics (United States)

Rajasekhar N.V.S. Suragani is an author at Acceleron Pharma (United States) specializing in medicine, cell signaling, and cell biology.

ORCID

Top concepts

Publications per year

2005–2021

13

Publications

13

Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis

Rajasekhar N.V.S. Suragani, Samuel M. Cadena, Sharon M Cawley et al. · Nature Medicine · 2014 · 421 citations

, , +8

Heme-regulated eIF2α kinase activated Atf4 signaling pathway in oxidative stress and erythropoiesis

Rajasekhar N.V.S. Suragani, Roshini S. Zachariah, Jason Velazquez et al. · Blood · 2012 · 161 citations · Full text

Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia

Rajasekhar N.V.S. Suragani, Sharon M Cawley, Robert Li et al. · Blood · 2014 · 142 citations · Full text

The function of heme-regulated eIF2α kinase in murine iron homeostasis and macrophage maturation

Sijin Liu, Rajasekhar N.V.S. Suragani, Fudi Wang et al. · Journal of Clinical Investigation · 2007 · 92 citations · Full text

, , +23

Follistatin-based ligand trap ACE-083 induces localized hypertrophy of skeletal muscle with functional improvement in models of neuromuscular disease

R. Scott Pearsall, Monique V. Davies, M. Cannell et al. · Scientific Reports · 2019 · 49 citations · Full text

Rows per page

1–5 of 13